Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Other Non Operating Income of -$89000.0 for Q1 2026, up 97.35% on a QoQ basis from -$3.4 million in Q4 2025, and down 61.82% year-over-year from -$233095.2 in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Other Non Operating Income history runs 18 years deep, the most recent figure standing at -$89000.0 for Q1 2026.
- Quarterly Other Non Operating Income fell 61.82% year-over-year to -$89000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.0 million (up 68.4% YoY) and the FY2025 annual result came in at $5.2 million, up 102.88% from the prior year.
- Other Non Operating Income was -$89000.0 for Q1 2026 at Alnylam Pharmaceuticals, up from -$3.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.6 million in Q4 2023 and bottomed at -$180.5 million in Q4 2024.
- A 5-year average of -$27.2 million and a median of -$1.6 million in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 201.61% — and 2024, when it tumbled 295380.0%.
- Alnylam Pharmaceuticals' Other Non Operating Income stood at -$1.6 million in 2022, then soared by 201.61% to $1.6 million in 2023, then plunged by 11094.58% to -$180.5 million in 2024, then soared by 98.14% to -$3.4 million in 2025, then surged by 97.35% to -$89000.0 in 2026.
- Business Quant data shows ALNY's Other Non Operating Income at -$89000.0 in Q1 2026, -$3.4 million in Q4 2025, and -$74.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89,000.00 |
| Dec 31, 2025 | -3.36 Mn |
| Sep 30, 2025 | -74.15 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Mar 31, 2025 | -55,000.00 |
| Dec 31, 2024 | -180.53 Mn |
| Sep 30, 2024 | -29.53 Mn |
| Jun 30, 2024 | -55.71 Mn |
| Mar 31, 2024 | -33,000.00 |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | -35.42 Mn |
| Mar 31, 2023 | 5,000.00 |
| Dec 31, 2022 | -1.62 Mn |
| Sep 30, 2022 | -76.60 Mn |
| Jun 30, 2022 | -34,000.00 |
| Mar 31, 2022 | -35,000.00 |
| Sep 30, 2021 | 17.72 Mn |
| Jun 30, 2021 | -58,000.00 |
| Mar 31, 2021 | 19.04 Mn |